The world signed a landmark global pandemic treaty to avoid repeating the catastrophic inequities of COVID-19, yet the entire agreement remains stuck in bureaucratic limbo. If you are wondering why world leaders cannot finish what they started, the answer comes down to a fierce tug-of-war over who gets life-saving vaccines and when.
During the early days of COVID-19, wealthy nations hoarded medical supplies while lower-income countries waited months or years for scraps. Seven months into global vaccine rollouts, high-income nations scooped up roughly 80% of available shots, leaving low-income regions with a mere 1%. The global pandemic agreement was designed to fix this exact imbalance. Countries agreed in principle that data on emerging pathogens must be shared rapidly, and that any resulting treatments or vaccines should be accessible to everyone. Don't forget to check out our earlier coverage on this related article.
The Sticking Point Called PABS
Agreeing on a concept is easy. Building the actual mechanism to execute it is where negotiations hit a wall.
The primary holdup centers on the Pathogen Access and Benefit-Sharing system, known as PABS. This system dictates how scientists and pharmaceutical corporations handle genetic sequences of new viruses. Wealthy nations, where most major pharmaceutical companies are headquartered, want an open, frictionless database. They argue that speed is everything when a new pathogen emerges, and putting legal strings on genetic data will only slow down scientific discovery. To read more about the context here, Associated Press offers an in-depth breakdown.
Lower-income countries see it differently. They remember being left behind. Representatives like Sangeeta Shashikant of the Third World Network point out that wealthy nations want immediate access to raw pathogen data without guaranteeing fair distribution of the resulting medical benefits.
What Lower-Income Nations Want
Countries in the Global South want strict conditions attached to pathogen data. One proposal involves placing genetic sequences into a closed or regulated database. Scientists and corporations could only access the data if they sign contracts committing to shared benefits. These contracts might require a set percentage of manufactured vaccines to go to the World Health Organization at cost or for free, alongside technology transfers so developing nations can manufacture their own treatments.
Wealthy governments balk at these requirements, claiming such mandates act as a tax on innovation and delay emergency responses. Meanwhile, side deals and bilateral agreements—such as those pursued outside the formal multilateral framework—threaten to undermine the entire treaty structure before it ever takes legal effect. Policy analysts have likened these separate arrangements to termites eating away at the foundation of global health cooperation.
What Happens Next
Negotiations are stretching forward, with upcoming deadlines prompting mounting pressure from health officials like WHO Director-General Tedros Adhanom Ghebreyesus, who has urged nations to finalize the annex. Every month of delay means the world remains vulnerable to the next health emergency without an enforceable equity framework in place.
Review current updates from the World Health Organization's Intergovernmental Working Group meetings, and track how your regional health ministry positions itself on benefit-sharing terms before the final deadlines arrive.
